{"id":998483,"date":"2026-08-27T08:15:08","date_gmt":"2026-08-27T12:15:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/milestone-pharmaceuticals-announces-data-presented-at-esc-congress-2026-on-the-impact-of-paroxysmal-supraventricular-tachycardia-psvt-on-patients-daily-lives-and-quality-of-life-between-epi\/"},"modified":"2026-08-27T08:15:08","modified_gmt":"2026-08-27T12:15:08","slug":"milestone-pharmaceuticals-announces-data-presented-at-esc-congress-2026-on-the-impact-of-paroxysmal-supraventricular-tachycardia-psvt-on-patients-daily-lives-and-quality-of-life-between-epi","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/milestone-pharmaceuticals-announces-data-presented-at-esc-congress-2026-on-the-impact-of-paroxysmal-supraventricular-tachycardia-psvt-on-patients-daily-lives-and-quality-of-life-between-epi\/","title":{"rendered":"Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients\u2019 Daily Lives and Quality of Life Between Episodes"},"content":{"rendered":"

\nResearch Shows that Patients with PSVT Experience a Substantial Burden Between Episodes, with Negative Impacts on Anxiety, Daily Activities, Sleep, and Work
\n<\/h2>\n
\n

MONTREAL\u00a0and\u00a0CHARLOTTE, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) — Milestone\u00ae <\/sup>Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) affects patients\u2019 daily lives and quality of life in the periods between episodes. The findings are being presented in a moderated ePoster session titled \u201cThe Impact of PSVT on Patients\u2019 Daily Life and QoL in Between Episodes\u201d at the European Society of Cardiology (ESC) Congress 2026<\/a> on August 30, 2026, 15:15-16:00 CET, Station 6, Research Gateway, Hall A1.<\/p>\n

\u201cThis study\u2019s findings broaden our understanding of the patient experience with PSVT and show that its impact can extend well beyond the acute episode,\u201d said Sean D. Pokorney, M.D., MBA, Assistant Professor of Medicine, Duke University Medical Center and the Duke Clinical Research Institute, and study presenter. \u201cThe changes patients reported in activities such as driving, travel and exercise, together with persistent anxiety between episodes, illustrate a burden that is not captured by looking at episode frequency or duration alone.\u201d<\/p>\n

PSVT is a common heart rhythm disorder in which the heart suddenly beats very fast affecting an estimated two million people in the United States. The acute symptoms of a PSVT episode are well recognized. However, the impact of living with the condition between episodes has not been well established. This study assessed patient-reported outcomes over nearly a year, capturing how PSVT shaped participants\u2019 activities, emotions, and quality of life outside of a healthcare setting. The results show that many people living with PSVT change their behavior, avoid everyday activities, and carry anxiety with them even when they are not having an episode.<\/p>\n

\n Key Findings <\/strong>\n <\/p>\n